Clinical Trial Update: Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sofosbuvir, daclatasvir, and ribavirin in hepatitis C patients with cirrhosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Tehran University of Medical Sciences | Conditions: Hepatitis C, Cirrhosis | Phase 3 | Status: COMPLETED